EMA/433934/2014

European Medicines Agency decision

P/0207/2014

of 8 August 2014

on the agreement of a paediatric investigation plan and on the granting of a waiver for valaciclovir (hydrochloride) (EMEA-001548-PIP01-13) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

European Medicines Agency decision

P/0207/2014

of 8 August 2014

on the agreement of a paediatric investigation plan and on the granting of a waiver for valaciclovir (hydrochloride) (EMEA-001548-PIP01-13) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Pharmathen S.A. on 10 October 2013 under Article 16(1) of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 20 June 2014, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for valaciclovir (hydrochloride), powder for oral suspension, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A waiver for valaciclovir (hydrochloride), powder for oral suspension, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Pharmathen S.A., Monumental Plaza Building A, 44 Kifisias Avenue, 15125 - Marousi, Attiki, Greece.

Done at London, 8 August 2014

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/215765/2014

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a waiver

EMEA-001548-PIP01-13

Scope of the application

Active substance(s):

Valaciclovir (Hydrochloride)

Condition(s):

Treatment and prevention of Herpes simplex virus disease

Treatment and prevention of Varicella Zoster virus disease

Pharmaceutical form(s):

Powder for oral suspension

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Pharmathen S.A.

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Pharmathen S.A. submitted for agreement to the European Medicines Agency on 10 October 2013 an application for a paediatric investigation plan for the above mentioned medicinal product.

The procedure started on 19 November 2013.

Supplementary information was provided by the applicant on 31 March 2014. The applicant proposed modifications to the paediatric investigation plan and requested a waiver.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 20 June 2014

On behalf of the Paediatric Committee
Dr Dirk Mentzer, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment and prevention of Herpes simplex virus disease

The waiver applies to:

- Newborn infants (from birth to less than 28 days);
- Powder for oral suspension, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

1.2. Condition:

Treatment and prevention of Varicella zoster virus disease

The waiver applies to:

- Newborn infants (from birth to less than 28 days);
- Powder for oral suspension, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition:

Treatment and prevention of Herpes simplex virus disease

2.1.1. Indication(s) targeted by the PIP

Treatment and prevention of Herpes simplex virus disease of the skin and mucous membranes

Treatment and prevention of recurrent genital herpes

Treatment and prevention of recurrent ocular Herpes simplex virus disease

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 28 days to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Powder for oral suspension

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	**Study 1** Development of a liquid age-appropriate oral formulation
Non-clinical studies	0	Not applicable.
Clinical studies	2	**Study 2** Randomized, Single Dose, Open label, 2 way cross-Over to evaluate the pharmacokinetic profiles and the relative bioavailability of an age-appropriate oral formulation of valaciclovir (study 1) using the marketed aciclovir suspension as the reference product (Zovirax) **Study 3** Open-label trial to evaluate pharmacokinetics, safety and tolerability of valaciclovir in children from 28 days to less than 12 years of age with or at risk for herpes simplex oral/labial or chickenpox infection.
Extrapolation, modelling and simulation studies	1	Modelling and simulation study to evaluate the use of the age-appropriate liquid formulation of valaciclovir for the treatment and suppression of infections caused by Herpes simplex virus and Varicella zoster virus in immunocompetent and immucompromised children from 1 month to less than 18 years of age
Other studies	0	Not applicable.

2.2. Condition:

Treatment and prevention of Varicella zoster virus disease

2.2.1. Indication(s) targeted by the PIP

Treatment and prevention of chickenpox

2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From 28 days to less than 18 years of age.

2.2.3. Pharmaceutical form(s)

Powder for oral suspension

2.2.4. Measures

Area	Number of measures	Description
Quality-related studies	1	**Study 1** Development of a liquid age-appropriate oral formulation
Non-clinical studies	0	Not applicable.
Clinical studies	2	**Study 2** Randomized, Single Dose, Open label, 2 way cross-Over to evaluate the pharmacokinetic profiles and the relative bioavailability of an age-appropriate oral formulation of valaciclovir (study 1) using the marketed aciclovir suspension as the reference product (Zovirax) **Study 3** Open-label trial to evaluate pharmacokinetics, safety and tolerability of valaciclovir in children from 28 days to less than 12 years of age with or at risk for herpes simplex oral/labial or chickenpox infection.
Extrapolation, modelling and simulation studies	1	Modelling and simulation study to evaluate the use of the age-appropriate liquid formulation of valaciclovir for the treatment and suppression of infections caused by Herpes simplex virus and Varicella zoster virus in immunocompetent and immucompromised children from 1 month to less than 18 years of age
Other studies	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By September 2017
Deferral for one or more measures contained in the paediatric investigation plan:	No